Safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base. - Aboshi M; Kawakami D; Kono K; Nishiyama A; Nogimori T; Sunada Y; Matsuda K; Sekida T; Suga S; Smith JF; Sato N; Yamamoto T; et al. (IScience, 2026)